Apeiron

This page shows the latest Apeiron news and features for those working in and with pharma, biotech and healthcare.

Keytruda and Opdivo backed for new uses in Europe

Apeiron Biologics also got the go-ahead for Dinutuximab beta as a treatment for high-risk neuroblastoma, an orphan indication.

Sanofi and Novartis snap up immuno-oncology candidates

BioNtech - signed last year alongside smaller deals with Selecta, Evotec and Apeiron Biologics.
Sanofi forges $1.5bn cancer partnership with BioNTech

Set to develop five cancer therapies
Sanofi and Evotec to work together on diabetes and cancer

Meanwhile, the two companies have also agreed to work together with Apeiron Biologics on novel, small-molecule immuno-oncology therapies. ... Sanofi will support two years of research funding for Evotec and Apeiron and could potentially yield more than
Advancing acquisitions

SPA/P2 (as combination). 350. Apeiron Biologics AG/GSK. APN01 - recombinant human angiotensin converting enzyme 2 (rhACE2) in ARDS.
GSK enters licensing deal for ARDS enzyme

GSK enters licensing deal for ARDS enzyme. Apeiron has granted GSK exclusive rights to its APN01 enzyme, in phase I development to treat Acute Respiratory Distress Syndrome. ... The deal will see GSK pay Apeiron an up-front payment of £11m cash and

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Pharma deals in August 2015

Immunology deals. In addition to this and in keeping with the industry fashion, Sanofi has ventured into immuno-oncology with Evotec / Apeiron Biologics. ... As a strategic collaboration it is fairly risk sparing and accesses Apeiron's immunological

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

BMS appoints CCO, Stephen Davies joins Eisai and more

Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... major near-term milestones of clinical-stage assets and support the expansion and
Apeiron bolsters management board

Apeiron bolsters management board. Peter Llewellyn-Davies joins as its CFO and CBO. ... Viennese cancer-immunotherapy focused group Apeiron Biologics has appointed a new chief financial officer and chief business officer in the form of Peter

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Add my company

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....